8-K: KALA BIO Secures $4.2M in Second Private Placement Closing

KALA BIO, Inc. completed the second closing of its private placement, raising $4.2 million, alongside significant board changes and an increase in authorized common stock.

Summary

• Completed the second closing of a private placement on January 30, 2026, raising $4.2 million in gross proceeds from the issuance of 2,100,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock at $2.00 per share.
• Each share of Series AAA Preferred Stock is convertible into 420 shares of common stock, for an aggregate total of 882,000,000 shares of common stock issuable upon conversion.
• This second closing, combined with the first closing on November 24, 2025 (which raised $1.8 million from 900,000 Series AA Preferred Stock shares convertible into 49,500,000 common shares), brings the total private placement proceeds to $6.0 million.
• Stockholders approved the issuance of common stock upon conversion of both Series AA and Series AAA Preferred Stock.
• Stockholders approved an amendment to the Restated Certificate of Incorporation to increase the number of authorized shares of common stock to 1,500,000,000 shares.
• Stockholders approved an amendment to effect a reverse stock split of the common stock at a ratio of not less than 1-for-2 and not greater than 1-for-100, at the Board of Directors' discretion.
• Six directors (Marjan Farid, M.D., Andrew I. Koven, Mark Iwicki, Todd Bazemore, C. Daniel Meyers, and Howard B. Rosen) resigned effective immediately following the Annual Meeting and upon approval of the Issuance Proposal and Share Increase Proposal.
• Five new directors nominated by AK Holdings Group Inc. were appointed to the Board: Avi Minkowitz (Class II), Hillel Posen (Class I), Chaim (Dovi) Berger (Class I), Yonatan Colman (Class III), and Brendan Purdy (Class III).
• New compositions for the Audit, Compensation, and Nominating and Corporate Governance Committees were established with the newly appointed directors.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development, primarily due to the explicit disclosure of severe financial distress, significant liabilities, and operational defaults, despite the capital raise. The board changes and impending reverse stock split further underscore the company's precarious position.

Positives

• Secured an additional $4.2 million in gross proceeds, completing the $6.0 million private placement, providing some capital infusion.
• Stockholder approval for the issuance of common stock upon conversion of preferred shares removes a significant hurdle for future conversions.
• Stockholder approval to increase authorized common stock to 1,500,000,000 shares enables the conversion of the preferred stock and provides flexibility for future equity actions.

Negatives

• The company explicitly acknowledges being in "severe financial distress," having "no unencumbered cash," and possessing "liabilities that likely far exceed the value of its assets."
• Six directors resigned, indicating a significant change in leadership and potentially a lack of confidence in the company's previous direction.
• The approval of a reverse stock split (up to 1-for-100) is typically a measure taken by companies with very low share prices, often signaling underlying financial or operational issues and can be perceived negatively by investors.
• The conversion of Series AA and Series AAA Preferred Stock could result in the issuance of over 930 million new common shares, representing substantial potential dilution for existing common stockholders.
• The company is in default on various obligations, and its landlord has locked it out of its California Facility, indicating severe operational and financial challenges.

Risks

• Severe financial distress, limited unencumbered cash, and liabilities likely far exceeding asset value, posing a significant going concern risk.
• Default on various obligations, including a lease agreement, leading to the company being locked out of its California Facility and potential legal action from the landlord.
• Significant potential dilution for existing common stockholders from the conversion of Series AA and Series AAA Preferred Stock into over 930 million common shares.
• Uncertainty regarding the effectiveness of a reverse stock split in improving long-term share price or investor sentiment, as it does not address fundamental business issues.
• The company has few remaining employees whose knowledge is limited, which could impact operational continuity and strategic execution.

Future Outlook

The company's stockholders approved a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-100, to be effected at the Board's discretion. This indicates a future action to potentially increase the per-share price of the common stock, likely to meet listing requirements. The company also needs to facilitate the conversion of preferred shares into common stock, which is now enabled by the increased authorized share count.

Management Comments

• Each of Messrs. Farid, Koven, Iwicki, Bazemore, Meyers and Rosens resignations was due to the approval of the Issuance Proposal and the Share Increase Proposal at the Annual Meeting and did not arise or result from any disagreement with the Company on any matters relating to the Companys operations, policies or practices.
• The Company has few remaining employees whose knowledge of the Company is limited, is in severe financial distress, has no unencumbered cash and has liabilities that likely far exceed the value of its assets, has incurred and continued to incur liabilities in the course of its wind-down.

Industry Context

StockSavvy.ai notes that the biotech industry often sees companies in various stages of development requiring significant capital. While capital raises are common, KALA BIO's situation, marked by severe financial distress, significant board turnover, and a pending reverse stock split, suggests a company facing existential challenges rather than typical growth-stage financing. The large conversion ratio for preferred stock and the need for a reverse split indicate a struggle to maintain market viability and investor confidence, contrasting with healthier biotech firms that raise capital for specific R&D milestones or commercialization efforts.

Comparison to Industry Standards

• The $6.0 million capital raise is relatively small compared to typical funding rounds for biotech companies, which often range from tens to hundreds of millions for clinical trials or product development.
• The significant board overhaul, with six directors resigning and five new ones appointed by a major investor (AK Holdings), is a substantial governance change, far exceeding routine board rotations seen in stable companies.
• The necessity for a reverse stock split (up to 1-for-100) is a strong indicator of a stock trading at a very low price, a situation often associated with companies struggling to meet minimum listing requirements, unlike many industry peers with robust market valuations.
• The explicit disclosure of "severe financial distress," "no unencumbered cash," and "liabilities that likely far exceed the value of its assets" is a stark contrast to the financial health typically reported by successful or even moderately performing biotech companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company states there is no action, suit, inquiry, notice of violation, proceeding, or investigation pending or threatened that (i) adversely affects or challenges the legality, validity, or enforceability of any of the Transaction Documents or the Shares or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.
• However, the company acknowledges that its landlord has delivered a notice of default and termination with respect to the Lease and has locked the company out of its California Facility, which could lead to legal proceedings.

Related Party Transactions

• The November 2025 Purchase Agreement involved an initial Series AA Investor who later transferred rights to AK Holdings Group Inc. AK Holdings then sold its rights to purchase Series AAA Preferred Stock to the Series AAA Investors, indicating a complex series of transactions involving specific investors.
• AK Holdings Group Inc. has the right to nominate up to eight directors, and five of their nominees were appointed to the Board, indicating significant influence by this investor.
• Settlement agreements were entered into by certain officers and directors of the Company in connection with the Securities Purchase Agreement dated November 23, 2025.

Stakeholder Impact

• Shareholders (Common Stock): Face significant potential dilution from the conversion of preferred stock (over 930 million common shares). The approved reverse stock split may temporarily boost share price but does not address fundamental value, and the explicit financial distress is a major concern.
• Preferred Stockholders (Series AA & AAA Investors): Have secured a significant stake and influence through board nominations. Their investment is convertible into a large number of common shares, giving them substantial upside if the company recovers, but also exposure to the stated financial distress.
• Employees: The company has "few remaining employees whose knowledge of the Company is limited," indicating potential job insecurity and operational challenges.
• Creditors: The company is in "severe financial distress" and has "liabilities that likely far exceed the value of its assets," suggesting high risk for creditors.
• Suppliers: The company is in "default in respect of various obligations," which could impact relationships with suppliers.
• Landlord (Menlo Prepi I, LLC): The company is in default on its lease, has not paid rent, and has been locked out of the California Facility, indicating a strained relationship and potential legal disputes.

Next Steps

• The Board of Directors is to determine the timing and specific ratio (between 1-for-2 and 1-for-100) for the approved reverse stock split.
• Facilitate the conversion of Series AA and Series AAA Preferred Stock into common stock, now enabled by stockholder approvals and the increased authorized share count.
• Address ongoing financial distress, liabilities, and operational defaults, including the landlord dispute and regaining access to the California Facility.

Key Dates

Recommendation

The filing explicitly details KALA BIO's "severe financial distress," "no unencumbered cash," and "liabilities that likely far exceed the value of its assets." The company is in default on various obligations, including its lease, leading to a lockout from a key facility. While a $6.0 million capital raise occurred, it is insufficient to offset the stated financial challenges. The significant potential dilution from preferred stock conversions (over 930 million common shares) and the approval of a reverse stock split (up to 1-for-100) are strong indicators of a company in a highly precarious position, facing potential delisting and severe value erosion for common shareholders. The extensive board changes, driven by a major investor, suggest a desperate attempt to restructure rather than a sign of fundamental improvement. These factors collectively point to a high risk of further capital loss for investors.

Keywords

KALA BIO, Private Placement, Series AAA Preferred Stock, Convertible Stock, Board Changes, Corporate Governance, Reverse Stock Split, Dilution, SEC Filing, Capital Raise, Financial Distress, Biotechnology